The document presents insights from HRA members regarding the multifaceted value proposition of funders, particularly in the context of early-stage and high-risk scientific research, as exemplified by the Foundation Fighting Blindness. While financial support remains central, funders contribute significantly beyond monetary grants by offering expertise in intellectual property (IP) placement, supporting infrastructure and supplies not covered by public funding, providing project guidance through advisory boards, and facilitating collaborations, knowledge-sharing workshops, and networking opportunities. These contributions aim to encourage innovation, cultivate young investigators, and advance research toward commercialization and public benefit.
The document outlines shared objectives and challenges between funders and research institutions—both strive to ensure that promising inventions can transition to commercialization and widen public access, yet may experience tension regarding IP agreements that could affect licensing prospects. To foster productive relationships and maximize research impact, practical resolutions are recommended, such as transparency in communication about funding, patenting, IP management, and licensee engagement, as well as clear policy articulation in agreement preambles. Mechanisms for regular reporting, confidentiality, and diligence in licensing agreements are emphasized to align funder and institution interests, support ongoing commercialization efforts, and ensure responsible stewardship of resources for patient benefit.
